Search alternatives:
improvement decrease » improvements increased (Expand Search), improvement success (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
sizes decrease » scores decreased (Expand Search), rivers decreased (Expand Search)
Showing 1 - 20 results of 7,423 for search '(( significant ((sizes decrease) OR (greater decrease)) ) OR ( significant improvement decrease ))', query time: 0.61s Refine Results
  1. 1
    Soil partice-size distribution.

    Soil partice-size distribution. by Yonggang Huang (223155)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Group-based descriptive statistics and effect sizes.

    Group-based descriptive statistics and effect sizes. by Murat Tutar (22250461)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Summary of significant treatment × time effect.

    Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

    Published 2024
    Save to List
    Saved in:
  4. 4
    Summary of significant single-arm time effect.

    Summary of significant single-arm time effect. by Wensheng Xiao (16557866)

    Published 2024
    Save to List
    Saved in:
  5. 5
    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size.

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

    Published 2025
    “…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”
    Save to List
    Saved in:
  6. 6
    Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups.

    Distribution of continuous variables of all 3 visits of group 1 (placebo) and group 2 (placebo) that have no significant difference among the groups. by Nattapon Riengvirodkij (11268720)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023.

    Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023.

    Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. by Heba Tallah Mohammed (2822432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i>

    JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> by Rayane Brinck Teixeira (6676529)

    Published 2025
    Save to List
    Saved in:
  10. 10
    Enrichment analysis of genes from the significant MS module.

    Enrichment analysis of genes from the significant MS module. by Lai Jiang (2401513)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Transition probabilities and class sizes for three-step LTA model (N = 432).

    Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: